

36th ANNUAL SYMPOSIUM ON THE CANNABINOIDS

Exhibition and Trade Center of Dijon 3 Bd de Champagne, 21000, Dijon,
France

Sunday, June 28, 2026

16:00	Registration Exhibition and Trade Center of Dijon 3 Bd de Champagne, 21000, Dijon, France
18:00 - 20:00	Welcome Reception Cellier de Clairvaux 27 Bd de la Trémouille, 21000 Dijon, France

Day 1. Monday, June 29, 2026

8:30-8:45	Welcome		
8:45-10:30	Session 1. The Endocannabinoid System: Medicinal Chemistry, Chemical Biology, AI & Drug Discovery Chairs: Uwe Grether & Malliga Iyer		
8:45-9:15	Session Keynote Presentation ORAL DECODING SUCCESS: THE NEW INGREDIENTS OF DRUG DISCOVERY ACCELERATING CLINICAL IMPACT THROUGH AI, HTE, CHEMICAL BIOLOGY, AND THE FIVE-STAR MATRIX	Uwe Grether	
9:15-9:30	BIOORTHOGONAL PROBES TO VISUALIZE ENDOCANNABINOIDS AND THEIR METABOLISM	Jeroen Punt	
9:30-9:45	CHEMICAL PROBES FOR VISUALIZING AND UNLOCKING THE MULTIFACETED ROLE OF MONOACYLGLYCEROL LIPASE	Marc Nazare	
9:45-10:00	A NOVEL CB2R-BASED APPROACH TO SUPPRESS LEUKOCYTE GUT-HOMING AND ATTENUATE INFLAMMATION IN CROHN'S DISEASE WITH STABILISED PEPTIDE ANTAGONISTS	David O'Connell	

10:00-10:15	UNBIASED IDENTIFICATION OF PUTATIVE CLINICAL BIOMARKERS OF TARGET ENGAGEMENT WITH THE SELECTIVE FATTY ACID-BINDING PROTEIN 5 INHIBITOR ART26.12	Myles Osborn	
10:15-10:30	INSIGHTS INTO THE TETRAHYDROPYRIDAZINE MOLECULAR SCAFFOLD CLASS OF PERIPHERAL CB1 ANTAGONISTS FOR THE TREATMENT OF METABOLIC DISORDERS	Malliga Iyer	
10:30-11:00	Coffee Break		
11:00-12:00	Session 2. Emerging Topics Chairs: Matt Hill & Mauro Maccarrone		
11:00-11:15	INVESTIGATING THE ROLE OF THE ENDOCANNABINOID SYSTEM IN THE PATHOPHYSIOLOGY OF RETINOPATHY OF PREMATURITY	Remi Karadayi	
11:15-11:30	IMPACTS OF CO-ADMINISTERED ALCOHOL AND VAPORIZED CANNABIS ON SIMULATED DRIVING ABILITY AND ABUSE LIABILITY	Halle Thomas	
11:30-11:45	INHIBITION OF DIAGLYCEROL LIPASE DISRUPTS THE HEAD-TWITCH RESPONSE INDUCED BY PSILOCYBIN	April Contreras	
11:45-12:00	HOW DOES CANNABIS USE AFFECT THE BRAIN'S REWARD SYSTEM? A 12-MONTH LONGITUDINAL FMRI STUDY OF ADULTS AND ADOLESCENTS WHO USE CANNABIS AND AGE-MATCHED CONTROLS	Martine Skumlien	
12:00-13:00	Presidential Plenary Lecture 1 A DRUGGABLE ACSL4 ISOFORM MOONLIGHTING FUNCTION FACILITATES ENDOCANNABINOID PLASMA-MEMBRANE DIFFUSION AND TUNES CB1 RECEPTOR SIGNALING	Jürg Gertsch	

13:00-14:30	Lunch		
14:30-15:45	Session 3. Medicinal Cannabis: Clinical Evidence & Applications Chairs: Carrie Cuttler & Ziva Cooper		
14:30-14:45	THE CANNABIDIOL FOR ACUTE PSYCHOSOCIAL STRESS AND NAUSEA (CAPSTAN) CLINICAL TRIAL	Zeeta Bawa	
14:45-15:00	ACUTE AND LONGER- TERM EFFECTS OF EDIBLE CANNABIS USE OF DIFFERING CANNABINOID RATIOS FOR OLDER ADULTS USING FOR PAIN, SLEEP, AND MOOD PROBLEMS	Angela Bryan	
15:00-15:15	PRIMARY RESULTS OF A RANDOMIZED CLINICAL TRIAL OF VAPORIZED CANNABIS VERSUS ORAL OXYCODONE FOR CHRONIC SPINE PAIN	Rachael Rzasa Lynn	
15:15-15:30	IMPACTS OF MINOR CANNABINOIDS AND TERPENES ON MENOPAUSE AND PERIMENOPAUSE SYMPTOMS	Matteya Proctor	
15:30-15:45	EXAMINING THE PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CANNABIGEROL (CBG) IN A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER CLINICAL TRIAL	Erika Lutz	
15:45-16:15	Mary E. Abood ICRS Women in Cannabinoid Research Award Lecture EMBRACING COMPLEXITY IN CANNABIS CLINICAL SCIENCE: USING MACHINE LEARNING TO IDENTIFY BIOMARKERS OF CANNABIS USE DISORDER	Cinnamon Bidwell	
16:15-16:30	Data Blitz 1		
	A PHASE 1 STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ART26.12; AN ORALLY DOSED FATTY ACID-BINDING PROTEIN 5 (FABP5) INHIBITOR	Saoirse O'Sullivan	
	MACHINE LEARNING METHODS TO INTEGRATE MULTI-OMIC DATA AND IDENTIFY TREATMENT MOLECULAR SIGNATURES IN A PSORIASIS MODEL	Myles Osborn	
	UNLOCKING THE ENDOCANNABINOID SYSTEM (ECS) WITH CHEMICAL PROBES	Yelena Mostinski	

	CHEMICAL BIOLOGY TOOLS TO STUDY GLYCEROPHOSPHODIESTERASE GDE4 AS A THERAPEUTIC TARGET IN PEDIATRIC NEURAL CANCERS	Aukje Beers	
	CANNABINOID SUBTYPE-2 (CB2R) RECEPTOR AGONISTS AS A STRATEGY TO FACE INFLAMMATION-BASED DISEASES: PROMISING IN VIVO EVIDENCE IN ALZHEIMER'S DISEASE AND IN GASTRIC CANCER	Marialessandra Contino	
	PERCEPTIONS REGARDING THE USE OF CANNABIS, ALCOHOL, AND TOBACCO DURING PREGNANCY AMONG WOMEN OF CHILD-BEARING AGE	Sharon Casavant	
	NAPE-PLD ACTIVATION BY MUSCARINIC RECEPTORS	Jim Wager-Miller	
	EVALUATING THE TUMOR ALTERING EFFECTS OF CANNABINOID AGONISTS (ACEA, JWH-133, CP55,940 and CANNABIDIOL) IN OUR BREAST (AT-3 CANCER CELL LINES) CANCER WILD-TYPE (C57BL/6J) MICE MODEL	Josee Guindon	
16:30-18:00	Coffee Break/Poster Session 1 *Odd numbered posters will be presented in the first 45 min (16:15) of the poster session and even numbered posters will be presented in the second half (17:15) of the session		
18:00	Free Evening		

Day 2. Tuesday, June 30

8:30-8:45	Opening Remarks		
8:45-9:15	<p>ICRS Mid-Career Award Lecture INTEGRATING ENDOCANNABINOID AND PHYTOCANNABINOID SCIENCE TO ADDRESS PAIN AND INFLAMMATION</p>	Steven Kinsey	
9:15-10:00	<p>Session 4. (Endo)Cannabinoids in Neurodegenerative Disorders Chairs: Julian Romero & Emma Puighermanal</p>		
9:15-9:30	<p>NEUROMETABOLIC ASPECTS OF CANNABIDIOL MECHANISMS IN A MITOCHONDRIAL DISEASE MODE</p>	Gunter Van der Walt	
9:30-9:45	<p>CHRONIC CANNABIDIOL RESTRUCTURES THE ENDOCANNABINOID LANDSCAPE IN AGED HIV-1 TAT TRANSGENIC MICE</p>	Barkha Yadav- Samudrala	
9:45-10:00	<p>CHRONIC NEUROINFLAMMATION IS REQUIRED TO ALLOW CB2-MEDIATED CONTROL OF IN VIVO MICROGLIAL FUNCTION</p>	Julian Romero	
10:00-10:30	<p>Session 5. Molecular Pharmacology of (Endo)Cannabinoids Chairs: Cecilia Hillard & Michelle Glass</p>		
10:00-10:15	<p>EXPLORING BIASED SIGNALING OF CLINICAL AGONISTS FOR THE CANNABINOID CB2 RECEPTOR WITH A NOVEL FUNCTIONAL MULTIPLEX ASSAY</p>	Lisa de Koning	
10:15-10:30	<p>NOVEL, POTENT CB1 ALLOSTERIC MODULATORS</p>	Ruth Ross	
10:30-11:00	Coffee break		

11:00-12:00	Session 6. (Endo)Cannabinoids in Neuropsychiatric Disorders Chair: Sachin Patel & Steve Alexander		
11:00-11:15	INVESTIGATING THE LINK BETWEEN EARLY LIFE STRESS, SOCIAL STRESS RESPONSE, AND IN-VIVO BRAIN FATTY ACID AMIDE HYDROLASE LEVELS IN INDIVIDUALS WITH SOCIAL ANXIETY DISORDER	Christina Pereira	
11:15-11:30	SYT-510, A CLINICAL CANDIDATE FOR A FIRST-IN-CLASS SELECTIVE ENDOCANNABINOID REUPTAKE INHIBITOR, DEMONSTRATE EFFICACY IN MULTIPLE PRECLINICAL CNS DISEASE MODELS AND A FAVORABLE PHASE 1 SAFETY PROFILE	Andrea Chicca	
11:30-11:45	A NOVEL CANNABINOID RECEPTOR 1 (CB1) PAM-ANTAGONIST DAMPENS AMPHETAMINE-INDUCED DOPAMINE LEVELS; EVIDENCE OF CB1-MEDIATED INDIRECT MODULATION OF HIGH DA STATES.	Catharine Mielnik	
11:45-12:00	THE ROLE OF THE ENDOCANNABINOID SYSTEM IN ALCOHOL USE DISORDER (AUD): NOVEL INSIGHTS FROM A PROSPECTIVE CLINICAL STUDY	Sara Kroll	
12:00-13:00	Kang Tsou Memorial Lecture PARKINSON'S DISEASE: FROM GENES TO PERSONALIZED TREATMENTS	Thomas Gasser	
13:00-14:30	Lunch		
14:30-15:00	Session 7. (Endo)Cannabinoids in Peripheral Organs: Homeostasis & Dysfunction Chairs: Yossi Tam & Katarzyna Starowicz		
14:30-15:45	ENDOCANNABINOID/CB1R OVERACTIVATION: FANNING THE FLAMES OF LUNG INFLAMMATION IN ALCOHOL USE DISORDER	Resat Cinar	
14:45-15:00	MAGL INHIBITION SUPPRESSES PSORIASIFORM INFLAMMATION VIA CB2	Eva Wisniewski	

15:00-15:15	INSULIN RESISTANCE AS A KEY DETERMINANT OF ENDOCANNABINOID OVERPRODUCTION IN OBESE VISCERAL ADIPOSE TISSUE	Romain Barbosa	
15:15-15:30	MITOCHONDRIA-ASSOCIATED CB1 RECEPTORS ARE NEW PLAYERS IN THE CONTROL OF ENERGY AND GLUCOSE METABOLISM	Camille Allard	
15:30-15:45	SPATIALLY RESOLVED PROTEOMIC ANALYSIS OF ENDOCANNABINOID SYSTEM MARKERS IN SALIVARY GLANDS OF PATIENTS WITH SJÖGREN'S SYNDROME	Natalia Malek	
15:45-16:15	Session Keynote Presentation TARGETING ENDOCANNABINOID SIGNALING AND CANNABINOID CB2 RECEPTORS IN LIVER, HEART, AND KIDNEY DISEASE: THERAPEUTIC POTENTIAL AND TRANSLATIONAL CHALLENGES	Pal Pacher	
16:15-16:30	Data Blitz 2		
	HEALTH IMPACT OF NEWLY STARTING MEDICINAL CANNABIS USE AMONG ADULTS WITH ANXIETY AND/OR PTSD – A LONGITUDINAL OBSERVATIONAL STUDY	Ryan Vandrey	
	FIRST REPORT OF OFF-LABEL CBD-RICH BROAD-SPECTRUM CANNABIS THERAPY IN RUBINSTEIN-TAYBI SYNDROME: CLINICAL OUTCOMES FROM A RARE GENETIC DISORDER	Micheline Donato	
	CHRONIC CBD MITIGATES AGE-ASSOCIATED DYSREGULATION OF NEUROINFLAMMATION IN A MOUSE MODEL OF GULF WAR ILLNESS	Kwang-Mook Jung	
	CHRONIC FAAH INHIBITION MODULATES NEUROINFLAMMATION IN AD MICE	M Teresa Grande	
	DIFFERENTIAL REGULATION OF ERK1/2 AND MKP-3 BY JWH-133 AND 2-AG REVEALS LIGAND-BIASED CANNABINOID TYPE 2 RECEPTOR SIGNALING IN MICROGLIA	Kaitlyn Partridge	

	TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED NEUROPSYCHIATRIC DISORDERS (TAND) OUTCOMES FOLLOWING ADJUNCTIVE CANNABIDIOL TREATMENT: 6-MONTH INTERMEDIATE ANALYSIS OF THE EPICOM TRIAL	Jennifer Triemstra	
	ENDOCANNABINOID MODULATION OF CUE-EVOKED FEAR IN A MOUSE MODEL OF ELEVATED DOPAMINE TONE	Stefan Vislavski	
	CARDIAC SURGERY-INDUCED ACUTE KIDNEY INJURY IN PEDIATRIC PATIENTS DISPLAYS EARLY SYSTEMIC ENDOCANNABINOID SYSTEM ELEVATION	Ariel Rothner	
	MONLUNABANT : A BETTER STRATEGY TO TACKLE TYPE 1 DIABETES?	Elise Wreven	
16:30-18:00	<p style="text-align: center;">Poster Session 2</p> <p>*Odd numbered posters will be presented during the first 45 min (15:45) of the poster session and even numbered posters will be presented in the second half (16:45) of the poster session</p>		
18:00	Free Evening		

Day 3. Wednesday, July 1

8:30-8:45	Opening remarks		
8:45-9:15	ICRS Lifetime Achievement Award Lecture CANNABINOID CHEMISTRY: FORM, FORMULATION, AND FUNCTION	Brian Thomas	
9:15-10:00	Session 8. New Insights into Brain Signaling via (Endo)Cannabinoids Chairs: Barna Dudok & Ozge Gunduz-Cinar		
9:15-9:30	DISSECTING THE ROLE OF CB1R EXPRESSING GABAERGIC INTERNEURONS IN THE BASOLATERAL AMYGDALA DURING FEAR EXTINCTION	Ozge Gunduz-Cinar	
9:30-9:45	ANALYZING NATURAL MOUSE BEHAVIOR USING MACHINE LEARNING AND POSE ESTIMATION: IMPACT OF THC AND ROLE OF ENDOCANNABINOID SIGNALING	Nephi Stella	
9:45-10:00	GLUTAMATERGIC SIGNALING ALTERATIONS IN CA1 PYRAMIDAL NEURONS MEDIATE THC INDUCED MEMORY IMPAIRMENT	Armin Kouchaeknejad	
10:00-10:30	Session 9. (Endo)Cannabinoids in Nociception & Pain Chairs: David Finn & Andrea Hohmann		
10:00-10:15	KLS 13019: A SYNTHETIC CBD ANALOGUE THAT REVERSES SYMPTOMS AND PRESERVES CHEMOTHERAPEUTIC EFFICACY IN NOVEL TRANSLATIONAL MODELS OF CIPN	Michael Ippolito	
10:15-10:30	CANNABIDIOL FOR SPINAL CORD INJURY CHRONIC NEUROPATHIC PAIN: A RANDOMIZED CLINICAL TRIAL	Iain McGregor	
10:30-11:00	Coffee break		
11:00-11:15	INHIBITION OF FATTY ACID BINDING PROTEIN 5 ALLEVIATES NEUROPATHIC PAIN FOLLOWING SPINAL CORD INJURY IN MICE	Martin Kaczocha	

11:15-11:30	Δ^9 -TETRAHYDROCANNABINOL AND CANNABIDIOL SYNERGISTICALLY ALLEVIATE HYPERALGESIA IN A HUMANIZED MOUSE MODEL OF SICKLE CELL DISEASE	Alex Mabou Tagne	
11:30-11:45	CANNABIDIOL ATTENUATES CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHIC PAIN THROUGH A MECHANISM THAT REQUIRES THE ENZYME N-ACYL PHOSPHATIDYLETHANOLAMINE-SPECIFIC PHOSPHOLIPASE D (NAPE-PLD)	Carlos Henrique Alves Jesus	
11:45-12:00	THC-INDUCED BEHAVIOR, PHYSIOLOGY, AND WITHDRAWAL EFFECTS ARE EXACERBATED BY RGS12 DELETION	Antonio Reck	
12:00-13:00	Mechoulam Award Lecture HARNESSING THE ENDOCANNABINOID SYSTEM TO COMBAT PAIN AND ADDICTION	Andrea Hohmann	
13:00-13:30	Business Meeting		
13:30	Boxed Lunch/Free Afternoon		

Day 4. Thursday, July 2

8:30-8:45	Opening remarks		
8:45-9:15	ICRS Early Career Award Lecture USING HUMAN LABORATORY STUDIES TO ADVANCE CANNABIS REGULATORY SCIENCE	Tory Spindle	
9:15-10:30	Session 10. Cannabis Exposure in Translational Models (Animal and Human Studies) Chairs: Renger Witkamp & Linda Klumpers		
9:15-9:30	CHRONIC VOLUNTARY CONSUMPTION OF CANNABINOIDS IN C57BL/6 MICE	Alayna Jones	
9:30-9:45	DELTA-9-TETRAHYDROCANNABINOL-SPARING EFFECTS OF CANNABIGEROL: A PLACEBO-CONTROLLED HUMAN LABORATORY STUDY	Elisa Pabon	
9:45-10:00	DETECTION OF PRENATAL CANNABIS EXPOSURE: IS MECONIUM A RELIABLE BIOMARKER?	Virginie Bouchard	
10:00-10:15	ADOLESCENT THC EXPOSURE INDUCES A MONOCYTE PHENOTYPE PRIMED FOR ENHANCED IMMUNE RESPONSE LATER IN LIFE	Rodrigo Klein	
10:15-10:30	CANNABIS EFFECTS ON OPIOID SELF-ADMINISTRATION: PILOT STUDY IN NON-DEPENDENT, OCCASIONAL OPIOID USERS	Shanna Babalonis	
10:30-11:00	Coffee break		

11:00-12:00	Session 11. (Endo)Cannabinoids in Neurodevelopment Chairs: Nephi Stella & Miriam Melis		
11:00-11:15	EVIDENCE OF BRAIN INJURY AND DYSREGULATION OF HOMEOSTATIC INFLAMMATORY MEDIATORS IN A PRECLINICAL MODEL OF PRENATAL CANNANOID EXPOSURE	Elise Weerts	
11:15-11:30	OMEGA-3 SUPPLEMENTATION COUNTERACTS PERSISTENT BEHAVIOURAL AND GUT-BRAIN ALTERATIONS PRODUCED BY ADOLESCENT EDIBLE THC EXPOSURE	Marieka DeVuono	
11:30-11:45	CANNABIDIOL EFFECTS UPON EXECUTIVE FUNCTION IN A CLINICAL TRIAL OF PEDIATRIC EPILEPSY AND COMORBID ANXIETY	Jay Salpekar	
11:45-12:00	DOES PRENATAL/PERINATAL ACETAMINOPHEN TREATMENT INHIBIT DIACYLGLYCEROL LIPASE ALPHA TO CAUSE ASD-LIKE BEHAVIORS IN MICE?	Michaela Dvorakova	
12:00-13:00	Presidential Plenary Lecture 2 SHINING FLUORESCENT LIGHT ON COLORFUL CANNABINOID SIGNALING	Istvan Katona	
13:00-14:30	Lunch		
14:30-15:30	Session 12. (Endo)Cannabinoids in Energy Metabolism & Cardiovascular Health Chairs: Tony Jourdan & Alessia Ligresti		
14:30-14:45	INTERIM ANALYSIS OF THE PHASE 2 CANCER APPETITE RECOVERY STUDY (CARES) EVALUATING ART27.13, A PERIPHERALLY SELECTIVE CANNABINOID AGONIST	Saoirse O'Sullivan	
14:45-15:00	CANNABINOID RECEPTOR β -ARRESTIN SIGNALING ALTERS CYTOKINE CONTROL OF METABOLIC AND INFLAMMATORY PATHWAYS	Gergő Szanda	

15:00-15:15	CB2 RECEPTOR ACTIVATION DRIVES MITOCHONDRIAL METABOLIC STRESS AND LIMITS AGGRESSIVE POTENTIAL IN COLORECTAL CANCER CELLS	Daniela Esposito	
15:15-15:30	NEW THERAPEUTIC TARGETS FOR HEPATIC FIBROSIS IN MASLD: THE SGLT2 COTRANSPORTER AND THE CANNABINOID-1 RECEPTOR. NEW THERAPEUTIC TARGETS FOR HEPATIC FIBROSIS IN MASLD: THE SGLT2 COTRANSPORTER AND THE CANNABINOID-1 RECEPTOR	Maéva Lorient	
15:30-15:45	Data Blitz 3		
	AGE MEDIATES EFFECT OF CB1 RECEPTOR DELETION ON FINE MOTOR LEARNING, SPINE DYNAMICS, AND NEURON-MICROGLIA PROXIMITY	Joanna Komorowska-Müller	
	DISTINCT IN VIVO SHORT-TERM PLASTICITY OF HIPPOCAMPAL CCK- AND PV-EXPRESSING BASKET CELL SYNAPSES	Barna Dudok	
	THE SELECTIVE FATTY ACID BINDING PROTEIN 5 INHIBITOR ART26.12 RELIEVES OSTEOARTHRITIS PAIN	Martin Kaczocha	
	DUALSTERIC CB1 POSITIVE ALLOSTERIC MODULATOR/CB2 AGONIST GAT1102 DISPLAYS BROAD SPECTRUM ANALGESIC EFFICACY WITHOUT PRODUCING CANNABIMIMETIC EFFECTS	Jonah Wirt	
	IMPACT OF CANNABIS USE FREQUENCY ON THE ANALGESIC EFFECTS OF SMOKED CANNABIS	Alisha Eversole	
	EFFECTS OF CHRONIC CANNABIS USE ON STRESS-INDUCED NEURAL AND IMMUNE RESPONSES IN RATS	Augustine Attah	
	CHRONIC DELTA-9-TETRAHYDROCANNABINOL EXPOSURE DURING ADOLESCENCE PRODUCES SELECTIVE BEHAVIORAL ABNORMALITIES IN ADULT NONHUMAN PRIMATES	Brian Kangas	
	THE EFFECT OF IN UTERO EXPOSURE TO THC ON THE DEVELOPMENT OF MIDBRAIN DOPAMINERGIC NEURONS	Susanne Hazenberg	

	EFFECTS OF ACUTE CANNABIS USE ON METABOLISM: A HUMAN METABOLOMICS STUDY	Jost Klawitter	
	CORRELATION BETWEEN BLOOD AND URINE CANNABINOIDS AND SUB-CLINICAL CARDIOVASCULAR BIOMARKERS IN HEALTHY YOUNG ADULTS IN THE HERBAL HEART STUDY	Amrit Baral	
15:45-17:15	<p style="text-align: center;">Poster Session 3</p> <p>*Odd numbered posters will be presented during the first 45 min (15:45) of the poster session and even numbered posters will be presented in the second half (16:30) of the poster session</p>		
19:00	<p style="text-align: center;">Gala Dinner Banquet Le Stade Gaston-Gérard 17 Rue du Stade, 21000 Dijon, France</p>		

Poster Session 1 - June 29, 2026

P1-1	CB2 AGONIST HU-910 RESOLVES PAIN EQUALLY TO MORPHINE IN MOUSE MODEL OF CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN.	Natalia Zemliana* and Natalya Kogan	
P1-2	PHARMACEUTICAL STABILIZATION OF ACIDIC CANNABINOIDS: ENABLING TRANSLATIONAL RESEARCH AND DEVELOPMENT	Benjamin Cameransi*	
P1-3	COMBINED AND SEPARATE EFFECTS OF CANNABIS AND TOBACCO: PSYCHOMOTOR, SUBJECTIVE AND PHYSIOLOGICAL OUTCOMES (CASE-CT): A PROTOCOL	Patricia Di Ciano*, Ahmed Hassan, Bernard Le Foll, Sergio Rueda, Michael Chaiton, Wei Wang, Christine Wickens, Justin Matheson, Pamela Kaduri, Sampson Zhao and Julia Migas	
P1-4	INVESTIGATION OF THE PSYCHEDELIC EFFECTS OF HIGH-DOSE DELTA-9 THC	David Wolinsky*, Zachary Daily, Joseph Ciancio, Kristy Arthur, Ryan Vandrey and Frederick Barrett	
P1-5	CONTROL OF CLINICAL SIGNS OF EARLY INFLAMMATORY BOWEL DISEASE IN NON-HUMAN PRIMATES USING CANNABIDIOL AND PREDNISOLONE	Tim Lefever, Diana Scorpio, Daniela Schwotzer, Judith Meriwether, Jacob McDonald, Trina Hazzah and Hunter Land	
P1-6	CB1 ANTAGONIST AM251 INHIBITS LOCOMOTION AND AFFECTS STEP KINEMATICS DURING CLIMBING IN MARKER-BASED 3D MOTION CAPTURE OF MALE MICE	Bogna Ignatowska-Jankowska*, Aysen Gurkan Ozer and Marylka Yoe Uusisaari	
P1-7	INTEGRATIVE TRANSFORMER-BASED MULTI-OMICS MODELING OF CANNABINOID AND ENDOCANNABINOID PATHWAYS FOR PRECISION PREVENTIVE HEALTH	Umesh Gangadhar, J Singh and P Kumar	

P1-8	THE SUBJECTIVE EFFECTS OF CANNABIS: A DOSE-RESPONSE META-REGRESSION	Isabella Goodwin, Dominic Oliver, Edward Chesney, Alexandra Gaillard, Simiao Wang, Andrea Wong Koo, Kat Petrilli*, Martine Skumlien, Amir Hossein Dakhili, Stina Wigroth, Stiliyana Obreshkova, Suhail Yusufzai, Ryan Vandrey, Michael Krausz, Tom Freeman, Philip McGuire, John Strang, Valentina Lorenzetti and Amir Englund	
P1-9	THE ROLE OF SEX AND THE PERIPHERAL CANNABINOID RECEPTOR (CB2R) ON NEUTROPHIL MATURATION IN MICE WITH SYSTEMIC C. ALBICANS INFECTION	Alexander Royas* and Nancy Buckley	
P1-10	OPTIMIZATION OF PERMEATION AGENTS FOR TRANSDERMAL DELIVERY OF THERAPEUTIC CANNABINOIDS	Madison Bulloch* and Rico Del Sesto	
P1-11	PHYTOCANNABINOID BIOMARKER DIFFERENCES BY PSYCHEDELIC USE STATUS AMONG DAILY CANNABIS CONSUMERS IN THE HERBAL HEART STUDY	Denise Vidot*, Amrit Baral, Briane Nicole Diggs, Marvin Reid, Winston De La Haye, Claudia Martinez and Lisa Reidy	
P1-12	ASSESSMENT OF IN VITRO GENOTOXICITY AND HEPATOTOXICITY AND IN VIVO SUBACUTE ORAL TOXICITY OF SYNTHETIC AND PLANT-DERIVED CANNABIDIOL	Wenhao Xia, David Bovard, Jenny Ho, Gitte Nykjær Nikolajsen, Sanne Skov Jensen, Blaine Phillips and Julia Hoeng	
P1-13	DEVELOPMENT OF SOLID CBD-LOADED PRO-NANO LIPOSPHERES WITH PRESERVED RELEASE AND BIOAVAILABILITY	Kathrine Kjær*, Awanish Kumar, Avi Domb, Benjamin Bugge Wahlqvist, Ee Tsin Wong, Wenhao Xia, Heidi Ziegler Bruun, Julia Hoeng and Sanne Skov Jensen	

P1-14	AFFECTIVE RESPONSES TO EXERCISE WHILE USING CANNABIS TRANSLATE TO SOCIAL COGNITIVE DETERMINANTS OF EXERCISE	Irene De La Torre*, Anika Sansgiry, Angela Bryan and Laurel Gibson	
P1-15	AN EXPLORATORY SENSORY EVALUATION OF CANNABINOID PRODUCTS WITH DIFFERENT FLAVOR VARIANTS	Pia Ingholt Hedelund* and Qiushuang Song	
P1-16	COMPREHENSIVE CHARACTERIZATION OF THE AROMA LANDSCAPE: INTEGRATING SENSORY ANALYSIS AND BIOSYNTHETIC PRECURSORS TO MAP THE VOLATILE PROFILES OF HEMP AND HIGH-THC CANNABIS	Thi Khanh Linh Tran, Amandine André, Elodie Gillich, Dániel Árpád Carrera, Irene Chetschik and Leron Katsir	
P1-17	INVESTIGATION OF CBD-ACCUMULATING CANNABIS SATIVA CULTIVARS AND SAFETY CONSIDERATIONS ON THE EFFECTS OF MINOR CANNABINOIDS	Patrik Szabó, Tivadar Kiss, Georgeta Pop and Dezső Csupor	
P1-18	UHPLC-PDA BASED SURVEY OF COMMERCIAL CBD PRODUCTS: METHODOLOGICAL VALIDATION AND LABEL ACCURACY ASSESSMENT	Ákos Bajtel, Róbert György Vida, András Fittler, Róbert Berkecz, Tivadar Kiss and Dezső Csupor	
P1-19	ADDRESSING THE CANNABIS EDUCATION GAP IN HEALTHCARE TRAINING PROGRAMS	Hannah Karam, Ethana Lam, Emily Lindley, Rachael Rzasz Lynn, David Kroll and Jacquelyn Bainbridge	
P1-20	WITHDRAWN		

P1-21	HEALTHCARE PROVIDER COMMUNICATION AND CANNABIS USE DURING PREGNANCY BY TRIMESTER: RESULTS FROM THE COVID-19 CANNABIS MOM STUDY	Renessa Williams*, Daniel King, Scheril Murray Powell, Charms Webbe, Genester Wilson-King, Melanie Dreher, Love Hawkins, Briane Nicole Diggs, Ciné Brown, Cynthia Lebron, Sarah Messiah and Denise Vidot	
P1-22	IMPACT OF CANNABIS USE ON THE VIRAL RESERVOIR AND IMMUNE CELL GENE EXPRESSION IN PEOPLE WITH HIV ON ANTIRETROVIRAL THERAPY	Urja Bhatt, David Murdoch, Cynthia Rudin, David Margolis, Sulggi Lee and Edward Browne*	
P1-23	TEMPORAL AND CELL-SPECIFIC FUNCTIONS OF CANNABINOID 1 RECEPTOR (CB1R) DRIVE THE TRANSITION FROM ACUTE KIDNEY INJURY TO FIBROSIS	Leïla Abbadi*, Marianne Wang, Myriam Dao, Sandrine Placier, Perrine Frere, Jessy Renciot, Souhila Ouchelouche, David Buob, Mylène Sagnard, Nesrine Shehata, Noel Zahr, Christos Chatzianoniou, Tony Jourdan, Muhammad Arif, Abhishek Basu, Resat Cinar and H��l��ne Francois	
P1-24	A PILOT RANDOMISED, CONTROLLED, SINGLE-CENTRE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS OF A NANO-EMULSIFIED CANNABIDIOL EDIBLE FORMULATION IN HEALTHY ADULTS	Kendrick Lee*, Indu Parmar, Zach LeBlanc and Jason Harquail	
P1-25	DELTA-TETRAHYDROCANNABINOL ALTERS CELL TYPE-SPECIFIC TRANSCRIPTOME AND CHROMATIN ACCESSIBILITY IN HUMAN IMMUNE CELLS	Mingrui Li, Xiaoke Duan, Jennifer Blackburn, Deepak D'Souza and Ke Xu	
P1-26	PERCEPTIONS REGARDING THE USE OF CANNABIS, ALCOHOL, AND TOBACCO DURING PREGNANCY AMONG WOMEN OF CHILD-BEARING AGE	Sharon Casavant*, Netsayi Kilembe, Natalie Shook and Steven Kinsey	

P1-27	NAPE-PLD ACTIVATION BY MUSCARINIC RECEPTORS	Jim Wager-Miller, Connor Schmitt, Elyssa Hyman, Ruyi Cai, YuLong Li, Ken Mackie and Alex Straiker	
P1-28	WITHDRAWN		
P1-29	EVALUATING THE TUMOR ALTERING EFFECTS OF CANNABINOID AGONISTS (ACEA, JWH-133, CP55,940 and CANNABIDIOL) IN OUR BREAST (AT-3 CANCER CELL LINES) CANCER WILD-TYPE (C57BL/6J) MICE MODEL	Hannah Quick, Robert Barnes, Aric Logsdon, Sharilyn Almodovar, Saba Javed and Josee Guindon*	
P1-30	A PHASE 1 STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ART26.12; AN ORALLY DOSED FATTY ACID-BINDING PROTEIN 5 (FABP5) INHIBITOR	Andrew Yates, Paula Daunt and Saoirse O'Sullivan*	
P1-31	MACHINE LEARNING METHODS TO INTEGRATE MULTI-OMIC DATA AND IDENTIFY TREATMENT MOLECULAR SIGNATURES IN A PSORIASIS MODEL	Myles Osborn, William Warren, Karina Gutheridge, Andrej Ondracka, Lorenzo Sani, Benjamin Tenmann, Andrew Yates and Saoirse O'Sullivan	
P1-32	UNLOCKING THE ENDOCANNABINOID SYSTEM (ECS) WITH CHEMICAL PROBES	Yelena Mostinski	
P1-33	CHEMICAL BIOLOGY TOOLS TO STUDY GLYCEROPHOSPHODIESTERASE GDE4 AS A THERAPEUTIC TARGET IN PEDIATRIC NEURAL CANCERS	Aukje Beers*, Thijmen van Kampen, Lianne Brussaard, Shruti Joshi, Lucas Vaughan, Wouter Driever, Jiayou He, Jarno Drost, Mario van der Stelt and Tom van der Wel	

P1-34	CANNABINOID SUBTYPE-2 (CB2R) RECEPTOR AGONISTS AS A STRATEGY TO FACE INFLAMMATION-BASED DISEASES: PROMISING IN VIVO EVIDENCE IN ALZHEIMER'S DISEASE AND IN GASTRIC CANCER	Giovanni Graziano, Francesco Mastropasqua, Annalisa Schirizzi, Lucie Crouzier, Cas van der Horst, Mariachiara Mammone, Antonio Laghezza, Maria Grazia Perrone, Giuseppe Felice Mangiatordi, Nicola Antonio Colabufo, Laura Heitman, Rosalba D'Alessandro, Tangui Maurice, Angela Stefanachi, Carmen Abate and Marialessandra Contino*	
P1-35	BOTANICALS: A KNOWLEDGE GRAPH-DRIVEN AI PLATFORM FOR NATURAL PRODUCT DRUG DISCOVERY	Srinivasan Ekambaram and Nikolay Dokholyan*	
P1-36	SIMULTANEOUS QUANTIFICATION OF FOUR ENDOCANNABINOIDS AND ENDOCANNABINOID CONGENERS TOGETHER WITH DELTA-9 TETRAHYDROCANNABINOL AND RELATED METABOLITES IN DRIED BLOOD SPOTS (DBS)	Alexandr Gish, Jean-Francois Wiart, Camille Richeval, Delphine Allorge and Jean-michel Gaulier	
P1-37	METABOLIC SIGNATURE OF PHYTOCANNABINOIDS IN KERATINOCYTES STUDIED BY 1H-NMR	Océane Quin*, Marylène Bertrand, Hervé Meudal, Lauriane Imbert-Roux, Jean-Yves Berton, Céline Landon and Catherine Grillon	
P1-38	A CANNABIDIOL COCRYSTAL (ART12.11) TABLET HAS COMPARABLE PHARMACOKINETICS TO EPIDIOLEX	Andrew Yates, William Warren, Myles Osborn and Saoirse O'Sullivan	
P1-39	INTEGRATIVE MULTI-OMICS ACROSS DIVERSE INDICATIONS IDENTIFIES LINOLEIC ACID AS CENTRAL LINK IN FATTY ACID-BINDING PROTEIN 5 INHIBITION	Myles Osborn*, William Warren, Heather Bradshaw, Martin Kaczocha, David Komatsu, Andrew Yates and Saoirse O'Sullivan	

P1-40	WITHDRAWN		
P1-41	<p>PRENATAL CANNABIS USE IS ASSOCIATED WITH INCREASED CIRCULATING ENDOCANNABINOIDS IN LATE PREGNANCY: FINDINGS FROM THE PROSPECTIVE CAN-B COHORT</p>	<p>Virginie Gillet, Dhyana Kpegba*, Aurélie Faucher, Viviane Verdant, Meg Haney, Claudia Lugo-Candelas, Jonathan Posner and Annie Ouellet</p>	
P1-42	<p>ADDRESSING BOTANICAL COMPLEXITY IN PURIFIED PHYTOCANNABINOID EXTRACTS THROUGH ADVANCED ANALYTICAL CHARACTERISATION</p>	<p>Renato dos Santos, Kasia Lach-Falcone and Julia Hoeng</p>	
P1-43	<p>BRAIN SELECTIVE SELENIUM-BASED MGL INHIBITION VIA AN ALLOSTERIC MECHANISM</p>	<p>Francesca Galvani, Saeed Al Masri, Edoardo Rocca, Lorenzo Tagliazucchi, Dominick D'Agosta, Silvia Rivara, Marco Mor and Daniele Piomelli*</p>	
P1-44	<p>DEVELOPMENT OF MONOACYLGLICEROL LIPASE DEGRADING PROTEOLYSIS TARGETING CHIMERAS</p>	<p>Lars van Abswoude*, Mirjam Huizenga, Axel Hentsch, Yannick Boer, Bogdan Florea, Joel Rüegger, Anna Stevens, Daan van der Vliet, Bruno Rosch, Youri van Baarle, Uwe Grether, Stephan Hacker, Monique Mulder, Marc Nazaré and Mario van der Stelt</p>	
P1-45	<p>RATIONAL OPTIMIZATION OF THE N-ADAMANTYL-ANTHRANIL AMIDE STRUCTURAL CORE FOR THE DEVELOPMENT OF NEW SELECTIVE LIGANDS FOR THE CANNABINOID SUBTYPE 2 RECEPTOR (CB2R)</p>	<p>Annalisa Fanizzi, Giovanni Graziano, Jose Brea, Alessia Ligresti, Chiara Riganti, Mabel Loza, Eddy Sotelo, Gemma Navarro, Maurice Tangui, Carmen Abate, Giuseppe Mangiatordi, Marialessandra Contino, Angela Stefanachi* and Francesco leonetti</p>	

P1-46	RTICBM-303, A CB1 RECEPTOR ALLOSTERIC MODULATOR, REDUCES CUE- AND DRUG-PRIMED REINSTATEMENT OF METHAMPHETAMINE SEEKING IN RATS	Thuy Nguyen, Subrata Roy, Ann Decker, Daniel Barrus, Maowei Wang, Tiffany Langston, Chi Hyuck Song, Jun-Xu Li and Yanan Zhang	
P1-47	WITHDRAWN		
P1-48	CHEMICAL PROBES TO VISUALIZE DIACYLGLYCEROL LIPASE	Nick Dominicus Franciscus Puijmbroeck*, Francesco Liberatori and Mario van der Stelt	
P1-49	PROBING THE RAT BRAIN SERINE HYDROLASE REPERTOIRE FOR ENDOCANNABINOID HYDROLASES	Stephen Alexander*, Qulayl Aldossari and Wafa Hourani	
P1-50	IN VIVO PROFILING OF PHYTOCANNABINOIDS IN MEDICINAL CANNABIS PLANTS VIA SOLID-PHASE MICROEXTRACTION APPROACH	Anna Roszkowska*, Katarzyna Woźniczka, Krzysztof Urbanowicz, Vaclav Trojan, Magdalena Kaszewska, Janusz Pawliszyn, Ryszard Tomasz Smoleński and Tomasz Bączek	
P1-51	DESIGN AND SYNTHESIS OF NATURE-INSPIRED ALKYLAMIDES FROM ZANTHOXYLUM PIPERITUM AND ACMELLA OLERACEA AS DUAL CB1/TRPV1 MODULATORS WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY	Lucia Abbatiello, Marika Del Vecchio, Salvatore Carandente Sicco, Daniela Esposito, Alessia Ligresti and Rosanna Filosa	

Poster Session 2 - Tuesday June 30, 2026

P2-1	HEALTH IMPACT OF NEWLY STARTING MEDICINAL CANNABIS USE AMONG ADULTS WITH ANXIETY AND/OR PTSD – A LONGITUDINAL OBSERVATIONAL STUDY	Ryan Vandrey, Clarissa Madar, Cerina Dubois, Matthew Lowe, Ivori Zvorski, Sasha Kalcheff-Korn, Heather Kimmel, C. Austin Zamarripa, Marcel Bonn-Miller, Justin Strickland and Johannes Thrul	
P2-2	FIRST REPORT OF OFF-LABEL CBD-RICH BROAD-SPECTRUM CANNABIS THERAPY IN RUBINSTEIN-TAYBI SYNDROME: CLINICAL OUTCOMES FROM A RARE GENETIC DISORDER	Micheline Donato*, Ruben Campo, Gessica Destro and Elton Silva	
P2-3	EVALUATING THE INDEPENDENT AND COMBINED EFFECTS OF THC AND CBD ON CHRONIC PAIN: PRELIMINARY EVIDENCE FROM A PROSPECTIVE COHORT OF OLDER ADULTS	Yan Wang*, Yancheng Li, Kimberly Sibille, Zhigang Li, Rene Przkora, Siegfried Schmidt, Margaret Lo, Erin Mobley, Jost Klawitter and Robert Cook	
P2-4	TOPICAL CANNABIDIOL ENHANCES AFFECTIVE TOUCH AND AUTONOMIC MEASURES WITHOUT CLEAR EVIDENCE OF PERIPHERAL AFFERENT MODULATION: A PLACEBO-CONTROLLED INVESTIGATION	Faiz Mohammed Kassim, Mattias Savallampi, Gaby Badre, Saad Nagi and Håkan Olausson	
P2-5	BASELINE STATES AS MODERATORS OF THE ACUTE EFFECTS OF CANNABIS ON ANXIETY AND MOOD IN THE LAB AND FIELD	Lily Makaryan and Carrie Cuttler	

P2-6	D-LIMONENE ATTENUATION OF THE ACUTE ADVERSE EFFECTS OF HIGH-DOSE ORAL Δ9-TETRAHYDROCANNABINOL (Δ9-THC)	C. Austin Zamarripa, Tory Spindle, Ethan Russo, Lakshmi Kumar, George Bigelow and Ryan Vandrey	
P2-7	CANNABIS EFFECTS ON CANCER BURDEN: RANDOMIZED CONTROLLED TRIAL PROTOCOL	Zin Myint*, Paul Nuzzo, Grayson Fuller, Hannah Harris, Lelia Andrews, Eli Christian, Donglin Yan, Jerod Stapleton and Shanna Babalonis	
P2-8	CANNABIS NURSE-LED AI HARM REDUCTION INTERVENTION DEVELOPMENT: MULTIDIMENSIONAL PERSPECTIVES OF ACCEPTANCE AND BARRIERS	Bria-Necole Diggs*, Denise Vidot, Ciné Brown, Scheril Powell, Melanie Dreher, Genester Wilson-King and Renessa Williams	
P2-9	PROBING THE IMMUNE, ANALGESIC, ABUSE-RELATED, AND DELTA-9-THC-SPARING EFFECTS OF TWO TERPENES, BETA-CARYOPHYLLENE AND MYRCENE, IN A PLACEBO-CONTROLLED HUMAN LABORATORY STUDY	Samantha L. Baglot, Katherine Hampilos, Stephanie Lake, Elisa Pabon, Alisha Eversole, Conor H. Murray, Paola Ruiz, Timothy Fong, Jennifer A. Fulcher and Ziva D. Cooper	
P2-10	LEVERAGING LARGE LANGUAGE MODELS TO CAPTURE CBD USE IN ELECTRONIC MEDICAL RECORDS	Cerina Dubois, Bernal Jimenez Gutierrez, Amrit Baral, Nazia Qureshi, Clarissa Madar, Nic Dobbins, Paul Nagy, Mark Dredze, Ryan Vandrey and Johannes Thrul	
P2-11	SYNERGISTIC EFFECTS OF THC AND CBD ARE ASSOCIATED WITH REDUCED CYTOKINES IN A CLINICAL SAMPLE WITH CHRONIC PAIN	Jonathon K. Lisano*, Carillon J. Skrzynski, Samantha N. Melendez, Angela D. Bryan and L. Cinnamon Bidwell	
P2-12	LONG-TERM PATTERNS AND COGNITIVE EFFECTS OF MEDICAL CANNABIS IN CHRONIC MUSCULOSKELETAL PAIN: A PROSPECTIVE COHORT STUDY	Ari Greis* and Asif Ilyas	

P2-13	CANNABINOID THERAPY IN BRODY'S DESEASE: A TRANSLATIONAL CASE REPORT OF A RARE GENETIC MYOPHATY	Jimmy F. Rocha* and Micheline F Donato	
P2-14	PRELIMINARY EVIDENCE FOR THE SAFETY AND TOLERABILITY OF A TOPICAL CANNABIGEROL FORMULATION IN MUSCULOSKELETAL PAIN MANAGEMENT	Frank Chen*, Roxy O'Rourke, Frantz Le Devedec and Karolina Urban	
P2-15	CANNABIS USE AND OBJECTIVELY MEASURED SLEEP AND CIRCADIAN ACTIVITY AMONG NON-HISPANIC BLACK WOMEN: RESULTS FROM CANNA-ESSENTIAL STUDY	Ciné Brown*, Bria-Necole A Diggs*, Amrit Baral*, Renessa Williams*, Judite Blanc*, Marvin Reid*, Girardin Jean-Louis* and Denise Vidot*	
P2-16	INNOVATIVE OROMUCOSAL NANOEMULSION FOR THE DELIVERY OF CANNABIS OILY EXTRACTS: FROM FORMULATION AND CHARACTERIZATION TO LONG-TERM CLINICAL ADHERENCE	Alessandra Spirito	
P2-17	EFFECTS OF CANNABIDIOL ON THREAT ANTICIPATION IN ALCOHOL USE DISORDER: A FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY	Tristan Hurzeler, Paul Haber and Kirsten Morley*	
P2-18	EFFECTS OF A CANNABIDIOL/TERPENE FORMULATION ON SLEEP IN AN ADOLESCENT WITH AUTISM SPECTRUM DISORDER	Nephi Stella and Paul Muchowski*	
P2-19	CARDIAC SURGERY-INDUCED ACUTE KIDNEY INJURY IN PEDIATRIC PATIENTS DISPLAYS EARLY SYSTEMIC ENDOCANNABINOID SYSTEM ELEVATION	Ariel Rothner*, Paulina Figueroa, Ines Reynoso, Ghaidaa Khatib, Shridhar Betkar, Philip Meier, Liad Hinden, Juerg Gertsch, Uri Pollak and Joseph Tam	

P2-20	MONLUNABANT : A BETTER STRATEGY TO TACKLE TYPE 1 DIABETES ?	Elise Wreven*, Jessica Ábalos Martínez, Valery Gmyr, Gianni Pasquetti, Nathalie Delalleau, Julien Thévenet, Anaïs Coddeville, François Pattou, Julie Kerr-Conte, Thomas Hubert and Isabel González Mariscal	
P2-21	ULTRASTRUCTURAL AND FUNCTIONAL EVIDENCE FOR MITOCHONDRIAL CANNABINOID-1 RECEPTORS MODULATING RENAL PROXIMAL TUBULE CELL METABOLIC HOMEOSTASIS	Ikenna Maduno*, Yael Friedmann, Oláh Attila, Liad Hinden and Joseph Tam	
P2-22	TESTING TOPICAL OR SYSTEMIC ADMINISTRATION OF ART26.12 – A FATTY ACID-BINDING PROTEIN 5 INHIBITOR – IN A MURINE MODEL OF ATOPIC DERMATITIS	William Warren*, Myles Osborn, Andrew Yates and Saoirse O'Sullivan	
P2-23	ENDOCANNABINOID RESPONSES TO RELIEF OF UPPER URINARY TRACT OBSTRUCTION (KIDNEY STONES)	Liad Hinden, Ariel Rothner, Sharon E. Fishberg, Eyal Atias, Alina Nemirovski, Ofer N. Gofrit, Guy Hidas and Joseph Tam	
P2-24	MÜLLER GLIAL CELLS ARE INVOLVED IN THE RETINAL ENDOCANNABINOID SYSTEM, POTENTIALLY THROUGH PLASMALOGEN-DEPENDENT MECHANISMS	Katia Ihadadene*, Julia Leemput, Lauriane Przegralek, Laurent Leclère, Claire Fenech, Benedicte Lorient, Jean-Paul Pais de Barros, Viviane De Almeida Bastos, Donna Pinheiro, Tony Jourdan, Xavier Guillonneau, Pascal Degrace, Niyazi Acar and Remi Karadayi	

P2-25	MATERNAL OBESITY DECREASES CIRCULATING ENDOCANNABINOIDS IN PREGNANT RATS AND DIFFERENTIALLY REGULATES PLACENTAL CANNABINOID RECEPTOR EXPRESSION	Lucas Lima, Letícia Alaburda, Juliana Gonçalves, Carmen Pazos-Moura, Cherley Andrade and Isis Trevenzoli*	
P2-26	CB2 RECEPTOR OF THE YOUNG PROMOTES INFLAMMATION IN PERIPHERAL NERVES DURING OBESITY	Haruka Hosoki*, Toru Asahi* and Chihiro Nozaki*	
P2-27	FOOD, SEX AND STRESS - SEASONAL DIFFERENCES OF BLOOD ENDOCANNABINOIDS AND ENDOCANNABINOID SYSTEM-ASSOCIATED LIPIDS IN VERVET MONKEYS	Philip Meier*, Maria Granell-Ruiz, Erica van de Waal and Jürg Gertsch	
P2-28	LOW-DOSE THCA PRESERVES PANCREATIC ISLET FUNCTION IN PROINFLAMMATORY CONDITIONS	Elise Wreven, Verónica Sánchez de Medina, Valery Gmyr, Gianni Pasquetti, Nathalie Delalleau, Julien Thévenet, Anaïs Coddeville, François Pattou, Julie Kerr-Conte, Thomas Hubert, Carlos Ferreira and Isabel González Mariscal*	
P2-29	THE INHIBITORY EFFECTS OF A PERIPHERALLY RESTRICTED CB1 RECEPTOR ANTAGONIST ON MYOFIBROBLAST TRANSDIFFERENTIATION OF HUMAN RETINAL PIGMENT EPITHELIAL CELLS	Dandan Zhao, Vishaka Motheramgari, Sarah Shrader, Wei Wang, Shigeo Tamiya and Zhao-Hui Song	
P2-30	CB1 RECEPTORS ON ADVILLIN- AND GPR65- POSITIVE SENSORY AFFERENTS OF THE GASTROINTESTINAL TRACT CONTROL VOLUNTARY ALCOHOL DRINKING IN MICE	George Kunos and Grzegorz Godlewski	

P2-31	CHRONIC CBD MITIGATES AGE-ASSOCIATED DYSREGULATION OF NEUROINFLAMMATION IN A MOUSE MODEL OF GULF WAR ILLNESS	Kwang-Mook Jung*, Heidi Avalos, Erica Squire, Hye-Lim Lee and Daniele Piomelli	
P2-32	CHRONIC FAAH INHIBITION MODULATES NEUROINFLAMMATION IN AD MICE	M Teresa Grande*, Laura Martín Pérez, Almudena López Escobar, Isabel Bravo Pérez-Plá, Laura Álvarez Gallardo, Iván Rodríguez Martín, Samuel Ruiz de Martín Esteban, Ana Martínez Relimpio and Julián Romero	
P2-33	EFFECTS OF CANNABINOIDS ON BIOMARKERS ASSOCIATED WITH COGNITION AND INFLAMMAGING IN OLDER ADULTS	Renee Martin-Willett*, Samantha Melendez, Grace MacDonald and Angela Bryan	
P2-34	MICROGLIAL CANNABINOID RECEPTOR 2 INFLUENCES ALPHA-SYNUCLEIN CLEARANCE	Marcelo Pachicano, Sol Reyes, Kelly B Menees, Moutaz Bellah Mohamed, Noelle Neighbarger and Valerie Joers*	
P2-35	CHRONIC FAAH INHIBITION REDUCES HIV-1 TAT-INDUCED NEUROINFLAMMATION AND MEMORY IMPAIRMENTS IN FEMALE MICE	Isabella Orsucci, Makayla Ma, Isabella Jakobuss, Aron Lichtman, Bogna Ignatowska-Jankowska, Barkha Yadav-Samudrala and Sylvia Fitting	
P2-36	CANNABIDIOL (CBD) PROMOTES ASTROCYTE VIABILITY AND SUPPRESSES INJURY-INDUCED ASTROCYTE STRESS RESPONSES IN ZEBRA FINCH SONG CONTROL NUCLEI	Dylan Marshall, Karen Litwa and Kenneth Soderstrom	
P2-37	ENDOCANNABINOIDS, MILD COGNITIVE IMPAIRMENT, AND DEMENTIA: A SPRINT COHORT STUDY	Jelena Klawitter, Garrett Wheeler, Michel Chonchol, Uwe Christians and Jost Klawitter	

P2-38	CANNABIS USE AND SUBJECTIVE COGNITIVE DECLINE AMONG MIDLIFE AND OLDER ADULT CANCER SURVIVORS	Hermine Poghosyan*, Elham Samam, Junlan Pu and Sayantani Sarkar	
P2-39	THE EFFECTS OF ENDOCANNABINOID AND PHYTOCANNABINOID MODULATION IN AN ACUTE MOUSE MODEL OF PARKINSON'S DISEASE	Lola Zovko*, Catharine Mielnik, Ruth Ross and Ali Salahpour	
P2-40	DIFFERENTIAL REGULATION OF ERK1/2 AND MKP-3 BY JWH-133 AND 2-AG REVEALS LIGAND-BIASED CANNABINOID TYPE 2 RECEPTOR SIGNALING IN MICROGLIA	Kaitlyn Partridge*, Cecilia Hillard and Allison Ebert	
P2-41	PHARMACOLOGICAL STUDY OF CANNABICHROMENE AND CANNABIGEROL AT THE SEROTONIN 1A (5-HT1A) AND ADENOSINE 2A (A2A) RECEPTORS	Riley Brown, Robert Laprairie and Kyle Boniface	
P2-42	NEURONAL VERSUS GLIAL CB2 RECEPTOR: INSIGHTS FROM A NEW STRAIN OF CB2-KO-EGFP REPORTER MICE	Zheng-Xiong Xi, Emily Linz, Haiying Zhang, Francisco Rubio, Qing-rong Liu and Bruce Hope	
P2-43	PHARMACOLOGICAL CHARACTERIZATION OF Δ 9-THC, Δ 8-THC, AND HHC SIDE-CHAIN HOMOLOGS AT CB1R AND CB2R CANNABINOID RECEPTORS	Oleh Durydivka, Ondrej Florian, Petr Palivec and Martin Kuchar	
P2-44	EFFECTS OF β -ARRESTIN AND GRK OVEREXPRESSION ON CANNABINOID RECEPTOR TYPE-1 (CB1) G ₁₃ ACTIVATION AND DESENSITIZATION KINETICS	Nora Radke* and Thomas Gamage	

P2-45	DISTINCT FUNCTIONAL PROFILES OF EMERGING SYNTHETIC CANNABINOIDS AND THEIR METABOLITES AT THE CANNABINOID RECEPTOR 1 (CB1R)	Szabolcs Dvorácskó*, Erika Micsinai and Tibor Varga	
P2-46	TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED NEUROPSYCHIATRIC DISORDERS (TAND) OUTCOMES FOLLOWING ADJUNCTIVE CANNABIDIOL TREATMENT: 6-MONTH INTERMEDIATE ANALYSIS OF THE EPICOM TRIAL	Agnies van Eeghen, Sarah ML Wilson, Stevie Roszkowski*, Maria Dunaway-Bryant, Kasia Wajer, Teresa Greco, Joanne Stevens, Lisa Moore-Ramdin and Petrus J de Vries	
P2-47	ENDOCANNABINOID MODULATION OF CUE-EVOKED FEAR IN A MOUSE MODEL OF ELEVATED DOPAMINE TONE	Stefan Vislavski, Catharine Mielnik, Ali Salahpour and Ruth Ross	
P2-48	CHRONIC SOCIAL STRESS ON FEAR MEMORY GENERALIZATION	Mohammed Sarikahya*, Rebecca Florea, Jina Javid, Sofiya Zbaranska, Paul Frankland and Sheena Josselyn	
P2-49	POLYGENIC RISK PREDICTORS OF INDIVIDUAL DIFFERENCES IN EFFECTS OF Δ -9-THC IN CONTROLLED LABORATORY STUDIES	Uri Bright*, Suhas Ganesh, Daniel F. Levey, Priya Gupta, Robin Murray, Marta Di Forti, Deepak Cyril D'Souza and Joel Gelernter	
P2-50	ESTABLISHING SELF-ADMINISTRATION OF CANNABIS VAPOR IN MALE AND FEMALE ADOLESCENT AND ADULT RATS	Zoë Campanella*, Catherine Hume, Ryan McLaughlin and Matthew Hill	
P2-51	DEPRESSIVE SIDE EFFECTS OF RIMONABANT EXPLAINED, AND REVERTED BY MDMA MICRODOSES	Irina Breido, Ronaldo Araujo, Natalia Zemliana, Albert Pinhasov and Natalya M. Kogan	

P2-52	CANNABIGEROL (CBG) ENHANCES DIVIDED ATTENTION IN RATS	Peter McLaughlin, Lily Bement, Laney Burns, Gemma DeSanzo, Katarina Lords, Amber McKay and Shali Slater	
P2-53	β -CARYOPHYLLENE ATTENUATES MK-801-INDUCED BEHAVIORAL DEFICITS IN A RAT MODEL OF SCHIZOPHRENIA	Magdalena Białoń*, Katarzyna Popiótek-Barczyk, Mateusz Królewski, Żaneta Broniowska, Agnieszka Wąsik and Katarzyna Starowicz	
P2-54	COMPARATIVE ANALYSIS OF WITHDRAWAL PROFILES IN NATURAL AND SYNTHETIC CANNABINOID USERS: INSIGHTS FROM A PROSPECTIVE CLINICAL STUDY AND SYSTEMATIC REVIEW	Rishi Sharma* and Aviv Weinstein	
P2-55	SYT-510, A CLINICAL CANDIDATE FOR A FIRST-IN-CLASS SELECTIVE ENDOCANNABINOID REUPTAKE INHIBITOR, DEMONSTRATES EFFICACY IN MULTIPLE PRELCLINICAL CNS DISEASE MODELS AND A FAVORABLE PHASE 1 SAFETY PROFILE	Ines Reynoso-Moreno, Celine Maeder, Fernando Quiñones-Olivera, Txomin Lalanne, Sandra Glasmacher, Simon Nicolussi, Celine Simonin, Jean-Louis Reymond, Jürg Gertsch and Andrea Chicca	

Poster Session 3 - July 2, 2026

P3-1	AGE MEDIATES EFFECT OF CB1 RECEPTOR DELETION ON FINE MOTOR LEARNING, SPINE DYNAMICS, AND NEURON-MICROGLIA PROXIMITY	Joanna Komorowska-Müller, Sophia Kaptain, Anna Lena Rottlaender, Anne-Kathrin Gellner, Andras Bilkei-Gorzo, Andreas Zimmer and Valentin Stein	
P3-2	DISTINCT IN VIVO SHORT-TERM PLASTICITY OF HIPPOCAMPAL CCK- AND PV- EXPRESSING BASKET CELL SYNAPSES	Mate Marosi, Shanii Tabb, Emre Agbas, Michelle Land, Francois StPierre and Barna Dudok	
P3-3	ENDOCANNABINOID AND FATTY ACID METABOLISM AS THERAPEUTIC TARGETS AFTER INTRAVENTRICULAR HAEMORRHAGE IN NEWBORNS	Angela Romero*, María de Hoz-Rivera, Laura Silva, María Martínez-Vega, Sofía Herrero, Beatriz Pérez-Calero, Roberta Verde, Fabiana Piscitelli and José Martínez-Orgado	
P3-4	INTEGRATED BEHAVIORAL AND MOLECULAR ANALYSIS OF PSILOCYBIN EFFECTS IN C57BL/6 WT MICE	Jakub Mlost*, Adam Wojtas, Shaima Islam, Yamen Levain, Zhaokun Wang and Iskra Pollak Dorocic	
P3-5	INTEGRATING GRAB SENSORS FOR THE STUDY OF ENDOCANNABINOID AND PURINERGIC SYSTEMS IN ASTROCYTES OF FAAH-DEFICIENT-ALZHEIMER'S DISEASE MICE	Ana M. Martínez-Relimpio*, Almudena López Escobar, Cristina Sánchez Martínez, Laura Martín Pérez, Isabel Bravo Pérez-Plá, Laura Álvarez Gallardo, Iván Rodríguez-Martín, Samuel Ruíz de Martín Esteban, M. Teresa Grande, Benjamin F. Cravatt, Yulong Li, Julián Romero	

P3-6	ENDOCANNABINOID SIGNALING DYNAMICS IN MOTOR CORTEX DURING DEXTEROUS BEHAVIOR	Subash Lamichhane and Jason Christie	
P3-7	SEX-DEPENDENT EFFECTS OF CB1 SIGNALING ON HIPPOCAMPAL NEUROGENESIS AND STRESS-RELATED BEHAVIOUR	Camilla Di Meo, Annamaria Tisi, Noemi De Dominicis, Eleonora Iucci, Cristina Urbano, Giacomo Cimino, Sergio Oddi and Mauro Maccarrone*	
P3-8	THE SELECTIVE FATTY ACID BINDING PROTEIN 5 INHIBITOR ART26.12 RELIEVES OSTEOARTHRITIS PAIN	Kai Bou, William Warren, Myles Osborn, Adam Bruzzese, Chris Gordon, Victoria Champan, Saoirse O'Sullivan, David Komatsu and Martin Kaczocha	
P3-9	DUALSTERIC CB1 POSITIVE ALLOSTERIC MODULATOR/CB2 AGONIST GAT1102 DISPLAYS BROAD SPECTRUM ANALGESIC EFFICACY WITHOUT PRODUCING CANNABIMIMETIC EFFECTS	Jonah Wirt, Ifeoluwa Solomon, Sumanta Garai, Idaira Oliva, Harvens Beauzile, John Hainline, Ganesh Thakur and Andrea Hohmann	
P3-10	IMPACT OF CANNABIS USE FREQUENCY ON THE ANALGESIC EFFECTS OF SMOKED CANNABIS	Alisha Eversole*, Stephanie Lake, Elisa Pabon, Conor Murray, Samantha Baglot, Katherine Hampilos, Timothy Fong and Ziva Cooper	
P3-11	EFFECTS OF ART27.13 IN A PRECLINICAL MODEL OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY	William Warren, Myles Osborn, Andrew Yates and Saoirse O'Sullivan	
P3-12	REPEATED MONOACYLGLYCEROL LIPASE INHIBITION REDUCES ALLODYNIA IN A MOUSE MODEL OF OPIOID-INDUCED HYPERALGESIA	Maria Jaakson, Matt Reck and Steven Kinsey	

P3-13	MONOACYLGLYCEROL LIPASE AS A POTENTIAL BIOMARKER AND THERAPEUTIC TARGET FOR SICKLE CELL DISEASE PAIN	Michael Taylor, Kennedy Goldsborough, Wally Smith and Aron Lichtman	
P3-14	ASSESSING THE ROLE OF NATURAL AND NATURE-INSPIRED COMPOUNDS FROM CANNABIS SATIVA L. AGAINST NEUROPATHIC PAIN	Federica Pellati, Giacomina Videtta, Chiara Sasia, Clarissa Caroli, Laura Bertarini, Paolo Governa, Alessia Agata Corallo, Lorenzo Corsi, Fabrizio Manetti, Claudia Mugnaini and Nicoletta Galeotti	
P3-15	SEX-SPECIFIC REGULATION OF OPIOID-INDUCED ADAPTATION BY MICROGLIAL CB2	Laura Boullon, Taylor J Woodward, Reese Barker, Julian Romero, Cecilia J Hillard, Ken Mackie and Andrea G Hohmann	
P3-16	CANNABIS EXPOSURE AND POSTSURGICAL PAIN: IMPLICATIONS FOR OPIOID USE AND ANALGESIC DEMAND	Daniel King	
P3-17	CHANGES IN MEDICATION USE IN OLDER ADULTS USING LEGAL MARKET CANNABIS FOR SLEEP, PAIN, AND MOOD	Anika* Sansgiry, Carillon Skrzynski, Renee Martin-Willett, Irene De La Torre and Angela Bryan	
P3-18	PILOT SAFETY OF INTRA-ARTICULAR CANNABIDIOL ALONE AND WITH TRIAMCINOLONE IN RODENTS FOR OSTEOARTHRITIS FEASIBILITY	Hunter Land, Natalia Malek, Jon Spears, Tim Lefever and Will Ramsey	
P3-19	EFFECTS OF CANNABINOIDS ON THE ANTINOCICEPTIVE AND ABUSE-RELATED BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF FENTANYL IN MICE	Rajeev Desai*, Evan Smith, Dalal AlKhelb, Emily Burke, Devin Morrison, Christos Iliopoulos-Tsoutsouvas, Michael Malamas, Spyros Nikas and Alexandros Makriyannis	

P3-20	EFFECTS OF ESTROUS CYCLE AND CHRONIC THC ON PAIN IN HIV-1 TG26 MICE	Havilah Ravula*, Barkha Yadav-Samudrala, Laith Sawaqed, Caitlin Huguely, William Lee, Asha Bora, Keller Hines, Isabella Orsucci, Gabriella Boyer, Justin Poklis, Wei Jiang and Sylvia Fitting	
P3-21	CHRONIC CANNABIDIOL TREATMENT RESTORES HIPPOCAMPAL NEUROTRANSMITTER BALANCE AND IMPROVES GAIT DYNAMICS IN A MOUSE MODEL OF NEUROPATHIC PAIN	Magdalena Białoń*, Ewelina Cyrano, Katarzyna Popiołek-Barczyk, Serena Boccella, Michaela Perrone, Antimo Fusco, Roozbe Bonsale, Ida Marabese, Sabatino Maione, Piotr Popik and Katarzyna Starowicz	
P3-22	PHARMACOLOGICAL STUDY OF ALLOSTERIC MECHANISMS AT THE TYPE 1 CANNABINOID RECEPTOR AND THEIR APPLICATION IN A MOUSE MODEL OF PAIN	Theodor Zaharia, Harvens Beauzile, Haley Anderson, Ganesh Thakur and Robert Laprairie	
P3-23	CANNABINOID CB1 RECEPTOR INVOLVEMENT IN THE BENEFICIAL EFFECTS OF ENRICHED ENVIRONMENT IN A RAT MODEL OF NEUROPATHIC PAIN	Annamária Liptáková*, Michelle Roche, Hugo Leite-Almeida and David Finn	
P3-24	2-AG AND 2-LG BASELINE AND POST-SHOCK COMPARISON BETWEEN CHRONIC PAIN AND HEALTHY CONTROL SAMPLES	Rahwa Netsanet, Taylor Woodward, Wenwen Du, Elyse Chafee, Jasmin Bola, Macie DeLillo, Heather Bradshaw, Joshua W. Brown	
P3-25	LIPIDOMIC PROFILING REVEALS DISTINCT ENDOCANNABINOID AND OXYLIPIN SIGNATURES IN HIP AND RIB FRACTURE TRAUMA	Victoria Chapman, James Turnbull, David A Barrett, Benjamin J Ollivere, Amy Zhang, Adeel Ikram, Tony Kelly, Jessica Nightingale, Waheed Ashraf and Ana M Valdes	

P3-26	5-HT _{1A} ACTIVITY IS INVOLVED IN ANTINOCICEPTION DUE TO CB ₂ , BUT NOT CB ₁ , ACTIVATION IN THE FORMALIN MURINE MODEL OF INFLAMMATORY PAIN	Robert Barnes, Hannah Quick and Josee Guindon*	
P3-27	EFFECTS OF CHRONIC CANNABIS USE ON STRESS-INDUCED NEURAL AND IMMUNE RESPONSES IN RATS	Augustine Attah*, Zach Fisher, Rebecca Kospore, Cole Eastman, Dani Lindenfelser and Ryan McLaughlin	
P3-28	CHRONIC DELTA-9-TETRAHYDROCANNABINOL EXPOSURE DURING ADOLESCENCE PRODUCES SELECTIVE BEHAVIORAL ABNORMALITIES IN ADULT NONHUMAN PRIMATES	Brian Kangas	
P3-29	OVARIAN STEROID MECHANISMS OF CANNABIS USE IN PSYCHIATRIC OUTPATIENTS	Anna Patterson*, Anisha Nagpal, Ashley Ross, Natania Crane and Tory Eisenlohr-Moul	
P3-30	SEX AND GENDER ANALYSIS OF COGNITIVE PERFORMANCE AND CANNABINOID CONCENTRATIONS THE MORNING AFTER SMOKING CANNABIS	Justin Matheson, Christina Zakala, Sampson Zhao, Adrien Nette, Alex Battistuzzi, Bernard Le Foll, Bruna Brands, Christine Wickens, Wei Wang, Sheng Chen and Patricia Di Ciano	
P3-31	THE CANNABIS BUNGEE JUMP STUDY: DOES BUNGEE JUMP STRESS RELEASE FAT-STORED Δ^9 -TETRAHYDROCANNABINOL	Eman Mshari, Caroline Copeland, Amir Englund*, Edward Chesney and Stephen Morley	
P3-32	TRAJECTORIES OF CANNABIS USE DURING PREGNANCY HIGHLIGHT DYNAMIC CHANGES IN BOTH MOTHERS AND PARTNERS: A WINDOW FOR INTERVENTION	Virginie Gillet, Marie-Laurence Bilodeau, Viviane Verdant, Claudia Lugo-Candelas, Jonathan Posner and Annie Ouellet*	

P3-33	CANNABINOID COMPOSITION DETERMINES THE ANTI-INFLAMMATORY EFFICACY OF HEMP EXTRACTS IN EXPERIMENTAL COLITIS	Shivani Godbole, Jackson Weaver and Wesley Raup-Konsavage*	
P3-34	BEST PRACTICES FOR GENERATING AND DELIVERING CANNABINOID AEROSOLS FOR IN VIVO SAFETY AND EFFICACY STUDIES	Blaine Phillips*, Wenhao Xia, Wei Teck Tan, Ee Tsin Wong and Julia Hoeng	
P3-35	STUDYING CONSUMMATORY BEHAVIOURS AND NEURONAL ACTIVITY FOLLOWING CANNABIS VAPOUR INHALATION IN MICE	Catherine Hume, Maya Botros, Cayden Murray and Matthew Hill	
P3-36	ACUTE CANNABIS VAPOUR EXPOSURE SELECTIVELY ENHANCES SOCIAL INVESTIGATION TOWARD UNFAMILIAR CONSPECIFICS IN MICE	Ibukun Akinrinade, Toni Cieplieski, Alexis Passmore, Matthew Hill	
P3-37	EXPLORING CANNABIDIOL AS A NOVEL THERAPEUTIC STRATEGY IN PROSTATE CANCER	Rianna Magee*, Joanne Cosgrave, Emma Lishman-Walker, Kelly Coffey, Craig Robson, David Galvin, Maria Prencipe and Antoinette Perry	
P3-38	THE ANTI-INFLAMMATORY EFFECTS OF FRENCH CANNABIS SATIVA EXTRACTS ON CYTOKINE RELEASE IN THP-1 MACROPHAGE-LIKE AND HUMAN PBMCs	Kossi Ayena*, Alicia Harry, Salma Abbouh, Chloé Robin, Clémence Couton, Jean-Baptiste Madinier, Guillaume Gabant, Carine Salliot and Lucile Mollet	
P3-39	HETEROGENEOUS TRAJECTORIES OF ANXIETY AND DEPRESSIVE SYMPTOMS AMONG PREGNANT CANNABIS USERS: LONGITUDINAL FINDINGS FROM THE CAN-B PROSPECTIVE COHORT	Virginie Gillet*, Anthony Gagnon, Virginie Bouchard, Claudia Lugo-Candelas, Jonathan Posner and Annie Ouellet	

P3-40	CONTRIBUTORS TO INTER SUBJECT PHARMACOKINETIC VARIABILITY IN ORAL CANNABIDIOL: EFFECTS OF FEEDING AND VEHICLE VOLUME IN RATS	Mingrui Guo, Olga Sirbu, Fiona Yu, June Chan, Maisarah Abdul Jalil, Kun Wei Tay, Wenhao Xia, Blaine Phillips, Julia Hoeng and Elizabeth Cairns*	
P3-41	CANNABIS AND EXPERIMENTAL PAIN: EFFECTS ON THE COLD PRESSOR TEST	Hannah Harris, Paul Nuzzo and Shanna Babalonis	
P3-42	PHYTOCHEMICAL PROFILE AND ENTOURAGE EFFECT: VARIOUS IMPACT OF FRENCH-APPROVED CBD-BASED DIETARY SUPPLEMENTS ON CHRONIC INFLAMMATION IN LONG-TERM VIRALLY SUPPRESSED PEOPLE LIVING WITH HIV (PLWH)	Chloé Robin, Clémence Couton, Kossi Ayena, Alicia Harry, Lamia El Khamlichi, Salma Abbouh, Jean-Baptiste Madinier, Barbara De Dieuleveult, Guillaume Gabant, Thierry Prazuck, Laurent Hocqueloux and Lucile Mollet	
P3-43	ORAL CANNABIDIOL TREATMENT AMELIORATED ALCOHOL-ASSOCIATED LIVER DISEASE THROUGH INTESTINAL AhR ACTIVATION	Wenke Feng	
P3-44	PROFILING OF ENDO- AND PHYTOCANNABINOIDS IN BRAIN AND BLOOD SAMPLES VIA SPME-LC-MS/MS METHOD	Magdalena Kaszewska*, Agnieszka Mosińska, Katarzyna Sztormowska, Katarzyna Smarzewska, Katarzyna Owczarek, Katarzyna Woźniczka, Vaclav Trojan, Tomasz Bączek and Anna Roszkowska	
P3-45	THE EFFECT OF IN UTERO EXPOSURE TO THC ON THE DEVELOPMENT OF MIDBRAIN DOPAMINERGIC NEURONS	Susanne Hazenberg*, Paul Lucassen, Marten Smidt, Simone Mesman and Rixt van der Veen	

P3-46	PIERCING NUCLEAR HERNIAS IDENTIFY ROLE OF ENDOCANNABINOID SIGNALING IN THE CYTOSKELETON FUNCTIONALITY AND DISORDER OF MIGRATING NEURONS	Yury Morozov*	
P3-47	CANNABINOID RECEPTOR TYPE 1 CHARACTERIZATION IN THE EARLY EMBRYO AND INFLUENCE ON CANNABINOID-MEDIATED CRANIOFACIAL DEFECTS	Kayla Richardson*, Eric Fish, Kevin Williams and Scott Parnell	
P3-48	CANNABIDIOL EXERTS A NEUROPROTECTIVE EFFECT ON MICROGLIA VIA REGULATION OF METABOLIC STATE	Michelle Cobb*, Riley Bessetti, Alexis Papariello, Ken Soderstrom and Karen Litwa*	
P3-49	PLACENTAL ENDOCANNABINOID DYSREGULATION AND MITOCHONDRIAL STRESS IN HUMAN PREGNANCY DISORDERS	Jessica Ábalos-Martínez, Elise Wreven, Fernando Bugatto, Francisco Visiedo, François Pattou, Julie Kerr-Conte, Luis Vazquez-Fonseca and Isabel González-Mariscal	
P3-50	CIRCULATING ENDOCANNABINOIDS AND CARDIOVASCULAR DISEASE RISK IN ADULTS WITH OVERWEIGHT OR OBESITY BEFORE AND AFTER A 1-YEAR EXERCISE TRIAL	Kevin Crombie*, Duck-chul Lee, Cecilia Hillard and Angelique Brellenthin	
P3-51	DUAL MAGL/HSL INHIBITOR LEI-515 PROTECTS AGAINST ATHEROSCLEROSIS	Jingxi Zhu, Mirjam Huizenga*, Xiaoke Ge, Mario van der Stelt, Sander Kooijman and Patrick Rensen	
P3-52	USE OF A CANNABIGEROL AND CANNABIDIOL FORMULATION ON MOTOR COORDINATION AND FATIGUE IN THE C56BL/6 MOUSE	Livia Blechinger*, Cameron MacLeod and Robert Laprairie	

P3-53	EFFECTS OF ACUTE CANNABIS USE ON METABOLISM: A HUMAN METABOLOMICS STUDY	Jost Klawitter, Laura Livelli, Cristina Sempio, Jelena Klawitter, Carlos Goncalves, Carillon Skrzynski, Madeline Stanger, Kent Hutchison and Angela Bryan	
P3-54	CORRELATION BETWEEN BLOOD AND URINE CANNABINOIDS AND SUB-CLINICAL CARDIOVASCULAR BIOMARKERS IN HEALTHY YOUNG ADULTS IN THE HERBAL HEART STUDY	Amrit Baral*, Lisa J. Reidy, Bria-Necole A. Diggs, Johannes Thrul, Sarah E. Messiah, Barry Hurwitz, Claudia Martinez and Denise C. Vidot	
P3-55	TARGETING BRAIN ENDOCANNABINOIDOME USING UHPLC-ESI-MS/MS	Laura Bertarini*, Giulia Bottai, Francesca Paola Cormio, Silvia Alboni and Federica Pellati	